Abstract 15782: Effects of Ezetimibe+Statins and Statin Therapy on Changes in Remnant-lipoprotein Cholesterol

Introduction: Elevated remnant-lipoprotein cholesterol (RLP-C, cholesterol mass in VLDL and IDL) increases cardiovascular disease (CVD) risk, particularly for patients with residual risk on lipid-lowering therapy (LLT). RLP-C assessment methods are not standardized and include measurement by immunoseparation (IM) and vertical auto profile ultracentrifugation (VAP [IDL+VLDL3]) or calculation (total cholesterol – HDL-C – LDL-C). This study assessed the effects of Eze, Eze + statins and statin monotherapy on RLP-C measured by these 3 methods in 1st line (statin naive/wash-out) and 2nd line (ongoing statin/uptitration) studies. Methods: RLP-C change and percent change from baseline were evaluated using pooled data from randomized 1st line (Eze vs placebo, Eze+statinsξ vs statinsξ) and 2nd line (Eze+statin‖ vs double statin¶ dose) studies. RLP-C was measured by all 3 methods for 1st line studies; VAP and calculated methods for 2nd line studies. Relationships between baseline covariates (lipids, hsCRP, age, gen...